Anti-angiogenic and anti-tumor properties of proteasome inhibitors

被引:33
作者
Daniel, KG
Kuhn, DJ
Kazi, A
Dou, QP
机构
[1] Wayne State Univ, Sch Med, Prevent Program, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA
关键词
cancer; chemotherapy; angiogenesis; anti-angiogenesis; proteasome; proteasome inhibitors; green tea; EGCG; Velcade (MLN-341); PS-341; copper; anti-copper drugs; VEGF;
D O I
10.2174/156800905774574075
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor growth and metastasis depend on the formation of blood vessels, angiogenesis, to supply the developing mass with nutrients, oxygen, and waste removal. The proteasome, a massive multisubunit catabolic body, exerts a regulatory influence on angiogenesis. Inhibition of the proteasome activity has been found to inhibit angiogenesis and induce apoptosis in human cancer cells with limited toxicity to normal cells. Therefore, the dual action of angiogenesis inhibition and cell death induction makes proteasome inhibition an attractive modality for chemotherapy. A variety of proteasome inhibitors have been studied including: antibiotics such as lactacystin, the green tea polyphenols, and the boronic acid Velcade (MLN-341). Most recently, certain classes of copper compounds have been found to act as potent proteasome inhibitors. The potential of particular organic compounds, such as 8-hydroxyquinoline, to spontaneously bind with tumor cellular copper and form proteasome inhibitors provides a new modality of anti-proteasome and anti-angiogenesis chemotherapy. This review examines angiogenesis, the proteasome, representative proteasome inhibitors, and the emerging role of copper. The formation of new blood vessels, or angiogenesis, is an important and necessary function in both embryonic development and wound repair [1, 2]. Therefore, the ability to regenerate or form new vessels for blood flow is essential. The control of angiogenic pathways is tightly regulated in normal differentiated adult cells, which generally do not stimulate blood vessel growth unless injury occurs. However, cancerous tissues stimulate angiogenesis that in turn leads to increased tumor formation and possible metastases [3]. Many of the factors involved in angiogenesis are regulated by the proteasome, which recently has become a focus in anti-cancer therapies due to its involvement in cell cycle and apoptosis control [4, 5]. Here we discuss angiogenesis and its relation to the proteasome. Additionally, current modalities of anti-angiogenic treatment, mainly proteasome inhibitory strategies, are reviewed. Furthermore, proteasome inhibitors, both natural and synthetic, and their anti-angiogenic effects as well as future approaches to anti-angiogenic chemotherapies are also discussed.
引用
收藏
页码:529 / 541
页数:13
相关论文
共 200 条
[1]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[2]   Proteasome inhibition in cancer: Development of PS-341 [J].
Adams, J .
SEMINARS IN ONCOLOGY, 2001, 28 (06) :613-619
[3]   Development of the proteasome inhibitor PS-341 [J].
Adams, J .
ONCOLOGIST, 2002, 7 (01) :9-16
[4]   Proteasome inhibition: a novel approach to cancer therapy [J].
Adams, J .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S49-S54
[5]   Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer [J].
Adams, J .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) :493-500
[6]   Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum [J].
Akopian, TN ;
Kisselev, AF ;
Goldberg, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (03) :1791-1798
[7]   The proteasome: a novel target for cancer chemotherapy [J].
Almond, JB ;
Cohen, GM .
LEUKEMIA, 2002, 16 (04) :433-443
[8]   Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts [J].
An, B ;
Goldfarb, RH ;
Siman, R ;
Dou, QP .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (12) :1062-1075
[9]   HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].
ANGIOLILLO, AL ;
SGADARI, C ;
TAUB, DD ;
LIAO, F ;
FARBER, JM ;
MAHESHWARI, S ;
KLEINMAN, HK ;
REAMAN, GH ;
TOSATO, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162
[10]  
[Anonymous], 1988, DEV BIOL